NCT07478107

Brief Summary

In gastrointestinal malignancies peritoneal diffusion represent a severe adverse event. Current methodoly including cytology of peritoneal fluid appears insufficient. It's crucial to individuate new technology.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
108

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jul 2024

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2024

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 31, 2025

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 28, 2026

Completed
12 days until next milestone

First Submitted

Initial submission to the registry

March 12, 2026

Completed
5 days until next milestone

First Posted

Study publicly available on registry

March 17, 2026

Completed
Last Updated

March 20, 2026

Status Verified

March 1, 2026

Enrollment Period

1.3 years

First QC Date

March 12, 2026

Last Update Submit

March 17, 2026

Conditions

Keywords

One-step nucleic acid amplificationOSNA assayGastrointestinal Malignancies

Outcome Measures

Primary Outcomes (1)

  • Sensitivity of both traditional cytology and OSNA assay to detect free cancer cells in the peritoneal fluid of patients with gastric or colon cancers.

    The OSNA assay was defined positive if at least a numer higher 160 cCP/µL was detected.

    The OSNA technique requires almost 30 minutes. Follow-up time of patients has a mean of 15 months.

Study Arms (1)

Gastric and colon cancer patients without macroscopic peritoneal diffusion

Examination of peritoneal washing with both traditional cytology and OSNA assay

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

University

You may qualify if:

  • Gastric and colon cancer patients with no evidence of peritoneal carcinomatosis undergoing surgery

You may not qualify if:

  • Oncological patients with overt peritoneal diffusion

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Campania "Luigi Vanvitelli"

Naples, Campania, 80131, Italy

Location

Related Publications (4)

  • Geca K, Skorzewska M, Rawicz-Pruszynski K, Mlak R, Sedlak K, Pelc Z, Malecka-Massalska T, Polkowski WP. Prognostic value of molecular cytology by one-step nucleic acid amplification (OSNA) assay of peritoneal washings in advanced gastric cancer patients. Sci Rep. 2022 Jul 21;12(1):12477. doi: 10.1038/s41598-022-16761-8.

    PMID: 35864130BACKGROUND
  • Galizia G, Lieto E, Auricchio A, Cardella F, Mabilia A, Podzemny V, Castellano P, Orditura M, Napolitano V. Naples Prognostic Score, Based on Nutritional and Inflammatory Status, is an Independent Predictor of Long-term Outcome in Patients Undergoing Surgery for Colorectal Cancer. Dis Colon Rectum. 2017 Dec;60(12):1273-1284. doi: 10.1097/DCR.0000000000000961.

    PMID: 29112563BACKGROUND
  • Kong D, Li Y, Yin S, Tan Y, Qu B, Huang L, Xi JJ, Wu A. Peritoneal Lavage Cytology Predicts Peritoneal Metastasis and is Associated with Poor Prognosis in Patients with Stage II-III Colorectal Cancer. Ann Surg Oncol. 2025 Dec;32(13):9712-9722. doi: 10.1245/s10434-025-18176-x. Epub 2025 Sep 1.

    PMID: 40887569BACKGROUND
  • Sugiyama Y, Tanabe K, Yanagawa S, Tazawa H, Toyota K, Kano M, Misumi T, Shishida M, Okano K, Hotta R, Ota H, Imaoka Y, Fukuda T, Takahashi S, Ohdan H. Prognostic factors and efficacy of postoperative chemotherapy in patients with gastric cancer with positive peritoneal cytology after gastrectomy. World J Gastrointest Oncol. 2025 Sep 15;17(9):110245. doi: 10.4251/wjgo.v17.i9.110245.

    PMID: 40977665BACKGROUND

MeSH Terms

Conditions

Peritoneal Neoplasms

Condition Hierarchy (Ancestors)

Abdominal NeoplasmsNeoplasms by SiteNeoplasmsDigestive System NeoplasmsDigestive System DiseasesPeritoneal Diseases

Study Officials

  • Gennaro Galizia, MD

    University of Campania Luigi Vanvitelli

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
23 Months
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Full Professor of Surgery

Study Record Dates

First Submitted

March 12, 2026

First Posted

March 17, 2026

Study Start

July 1, 2024

Primary Completion

October 31, 2025

Study Completion

February 28, 2026

Last Updated

March 20, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will share

all data will be shared after publication

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
Time Frame
one month after publication
Access Criteria
email gennaro.galizia@unicampania.it

Locations